09-Jun-2020 - Charité - Universitätsmedizin Berlin

Could the blood of COVID-19 patients be used to predict disease progression?

Study discovers differences in the blood samples of severe and mild cases

Researchers from Charité – Universitätsmedizin Berlin and the Francis Crick Institute have identified 27 proteins which are present at different levels in the blood of COVID-19 patients, depending on the severity of their symptoms. These biomarker profiles could be used to predict disease progression and make it easier for doctors to decide which type of treatment to use.

People respond very differently to infection with the novel coronavirus (SARS-CoV-2). While some patients develop no symptoms at all, others will develop severe disease and may even die. For this reason, there is an urgent need for ‘biomarkers’, quantifiable biological characteristics which could provide a reliable means of predicting disease progression and severity. A research team led by Prof. Dr. Markus Ralser (Director of Charité’s Institute of Biochemistry, holder of an Einstein Professorship and Group Leader at the Francis Crick Institute) used state-of-the-art analytical techniques to rapidly determine the levels of various proteins in the blood plasma. This approach enabled the researchers to identify various protein biomarkers in the blood plasma of patients with COVID-19 which were linked to the severity of their disease.

The researchers developed a precise, high-throughput mass spectrometry platform capable of analyzing the patients’ proteomes – the compendium of proteins found in biological material – at a rate of 180 samples per day. Using this technology, the team analyzed blood plasma samples from 31 men and women who were receiving treatment at Charité for COVID-19 of varying degrees of severity. The researchers were able to identify 27 proteins in the blood which varied in quantity depending on disease severity. The researchers then validated these molecular signatures by analyzing samples from another group of 17 COVID-19 patients and 15 healthy people. Protein expression signatures were able to precisely classify patients according to the World Health Organization’s coding criteria for COVID-19.

“These results lay the foundations for two very different applications. One possible future use would be for disease prognosis,” explains Prof. Ralser, who is also group leader at the Francis Crick Institute in London. “An early blood test would enable the treating physician to predict whether or not a patient with COVID-19 will develop severe symptoms. This could potentially save lives: the sooner physicians know which patients will require intensive care, the faster they can make use of the available treatment options.” In order to get closer to this goal, the researchers will now study how the biomarker signatures change over the course of the disease.

“Another possible future use would be as an in-hospital diagnostic test, which could provide clarity regarding a patient’s condition – regardless of how they themselves describe it,” explains the biochemist. He adds: “In some cases, a patient's symptoms do not appear to provide an accurate picture of their true health status. An objective evaluation, based on their biomarker profile, could be extremely valuable in this regard.” The research team now plan to test their new method in a larger number of patients in the hope of getting closer to developing a diagnostic test.

Changes in the protein profile

Some of the 27 proteins which were found to predict the severity of COVID-19 had not previously been linked to an immune response. However, the biomarkers identified by the researchers also included clotting factors and regulators of inflammation. Some of these proteins act on interleukin 6 (IL-6) at the molecular level. IL-6 is a protein which is known to cause inflammation, and which, according to preliminary studies, is associated with severe COVID-19 symptoms. A number of the biomarkers identified as part of this study might therefore be suitable targets for treatment.

Facts, background information, dossiers
  • blood
  • blood analysis
  • Covid-19
More about Charité
  • News

    COVID-19: Immune system on the wrong track

    Contrary to what has been generally assumed so far, a severe course of COVID-19 does not solely result in a strong immune reaction – rather, the immune response is caught in a continuous loop of activation and inhibition. Experts from Charité – Universitätsmedizin Berlin, the University of ... more

    HIV-1: The undercover agent

    Antibodies are not the only protection against viruses: At a much earlier stage, infected cells detect components of a virus with the help of internal sensors and trigger an immune response. This is an element of what is known as innate immunity, and helps prevent viruses from spreading fur ... more

    Cleaning craze in the brain

    Synapses consist of hundreds of different proteins. For correct transmission of brain signals, their building blocks must constantly be checked for functionality and replaced by new ones. A team of researchers from the Leibniz Institute of Neurobiology Magdeburg, the German Centre for Neuro ... more

  • Research Institutes

    Charité - Universitätsmedizin Berlin

    The Charité is one of the largest university hospitals in Europe. Here, 3800 doctors and scientists heal, do research and teach at the top international level. More than half of the German Nobel Prize winners in medicine and physiology come from the Charité, among them Emil von Behring, Ro ... more

More about The Francis Crick Institute
  • News

    Stem cells in human embryos commit to specialization surprisingly early

    Our biological history can be traced back to a small group of cells called embryonic stem cells, which through cell division, give rise to cells that specialise to perform a specific role in the body - a process known as differentiation. Understanding when and how embryonic stem cells speci ... more

    Molecular 'magnets' could improve cancer immunotherapy

    Chemicals that attract specialised immune cells toward tumours could be used to develop better immunotherapies for cancer patients, according to new research. Scientists at the Francis Crick Institute have discovered that immune cells called Natural Killer cells accumulate in tumours and re ... more

    Chemo-boosting drug discovered for leukemia

    Drugs developed to treat heart and blood vessel problems could be used in combination with chemotherapy to treat an aggressive form of adult leukemia, new research led by the Francis Crick Institute reveals. In a study published in Cancer Cell, researchers at the Francis Crick Institute, Ki ... more

  • Research Institutes

    The Francis Crick Institute

    The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. Its work is helping to understand why disease develops and to find new ways to treat, diagnose and prevent illnesses such as cancer, heart disease, stroke, ... more